Joan Bargay
A5035866456- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Acute Myeloid Leukemia Research
- Chemokine receptors and signaling
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Hematopoietic Stem Cell Transplantation
- Peptidase Inhibition and Analysis
- Chronic Myeloid Leukemia Treatments
- Cancer Treatment and Pharmacology
- Acute Lymphoblastic Leukemia research
- Chronic Lymphocytic Leukemia Research
- Histone Deacetylase Inhibitors Research
- Cancer Genomics and Diagnostics
- HIV/AIDS drug development and treatment
- Hemoglobinopathies and Related Disorders
- Monoclonal and Polyclonal Antibodies Research
- CNS Lymphoma Diagnosis and Treatment
- T-cell and B-cell Immunology
- Immunodeficiency and Autoimmune Disorders
- Neutropenia and Cancer Infections
- Viral-associated cancers and disorders
- Lung Cancer Treatments and Mutations
- CAR-T cell therapy research
- vaccines and immunoinformatics approaches
Hospital Son Llatzer
2016-2025
Health Research Institute of the Balearic Islands
2020-2024
Hospital Universitario Son Espases
2021
Universitat de les Illes Balears
2021
Research Institute of Health Sciences
2020
Rigshospitalet
2011
Azienda Ospedaliero-Universitaria Careggi
2011
Universidad de Salamanca
2008
Hospital Universitario Son Dureta
1991-2007
Hospital Can Misses
2007
For patients with smoldering multiple myeloma, the standard of care is observation until symptoms develop. However, this approach does not identify high-risk who may benefit from early intervention.In randomized, open-label, phase 3 trial, we randomly assigned 119 myeloma to treatment or observation. Patients in group received an induction regimen (lenalidomide at a dose 25 mg per day on days 1 21, plus dexamethasone 20 4 and 12 15, 4-week intervals for nine cycles), followed by maintenance...
Assessing measurable residual disease (MRD) has become standard with many tumors, but the clinical meaning of MRD in multiple myeloma (MM) remains uncertain, particularly when assessed by next-generation flow (NGF) cytometry. Thus, we aimed to determine applicability and sensitivity MRD-negative criterion defined International Myeloma Working Group (IMWG).In PETHEMA/GEM2012MENOS65 trial, 458 patients newly diagnosed MM had longitudinal assessment after six induction cycles bortezomib,...
PURPOSE Patients with multiple myeloma (MM) may show patchy bone marrow (BM) infiltration and extramedullary disease. Notwithstanding, quantification of plasma cells (PCs) continues to be performed in BM since the clinical translation circulating tumor (CTCs) remains undefined. PATIENTS AND METHODS CTCs were measured peripheral blood (PB) 374 patients newly diagnosed MM enrolled GEM2012MENOS65 GEM2014MAIN trials. Treatment included bortezomib, lenalidomide, dexamethasone induction followed...
Multiple myeloma is a treatable, but currently incurable, hematological malignancy of plasma cells characterized by diverse and complex tumor genetics for which precision medicine approaches to treatment are lacking. The Myeloma Research Foundation's Relating Clinical Outcomes in Personal Assessment Genetic Profile study ( NCT01454297 ) longitudinal, observational clinical newly diagnosed patients with multiple (n = 1,143) where samples using whole-genome sequencing, whole-exome sequencing...
// Marina Díaz-Beyá 1, 2 , Salut Brunet 2, 3 Josep Nomdedéu 4 Marta Pratcorona Anna Cordeiro 5 David Gallardo 6 Lourdes Escoda 7 Mar Tormo 8 Inmaculada Heras 9 Maria Ribera 10 Rafael Duarte 11 María Paz Queipo de Llano 12 Joan Bargay 13 Antonia Sampol 14 Meritxell Nomdedeu 1 Ruth M. Risueño Montserrat Hoyos Jorge Sierra Mariano Monzo Alfons Navarro 5, * Jordi Esteve 15, on behalf of the Cooperative AML group CETLAM Hematology Department, Hospital Clinic,...
Abstract Monitoring of the monoclonal protein (M-protein) by electrophoresis and/or immunofixation (IFE) has long been used to assess treatment response in multiple myeloma (MM). However, with use highly effective therapies, M-protein becomes frequently undetectable, and more sensitive methods had be explored. We applied IFE mass spectrometry (EXENT&FLC-MS) serum samples from newly diagnosed MM patients enrolled PETHEMA/GEM2012MENOS65 obtained at baseline (n = 223), after induction 183),...